Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 6/20 | 0.52 |
| ▸ | CDK9 | P50750 | 3/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.51 |
| ▸ | CDK2 | P24941 | 6/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605794 | 0.85 | CDK5 (0.58) | CDK5CDK9GSK3AGSK3BDYRK1A | |
| SCHEMBL7758141 | 0.78 | CCNA2 (0.76) | CDK5GSK3AGSK3BCCNA2CDK2 | |
| SCHEMBL27589430 | 0.75 | CCNA2 (0.51) | CDK5GSK3AGSK3BCCNA2CDK2 | |
| SCHEMBL1250465 | 0.74 | CDK5 (0.74) | CDK5GSK3AGSK3BCCNA2CDK2 | |
| SCHEMBL6608787 | 0.74 | CDK5 (0.67) | CDK5GSK3AGSK3BCCNA2CDK2 | |
| SCHEMBL6617604 | 0.73 | CCNA2 (0.66) | CDK5GSK3AGSK3BCCNA2CDK2 | |
| SCHEMBL1251123 | 0.73 | MAPT (0.64) | CDK5GSK3AGSK3BCCNA2CDK2 | |
| SCHEMBL6607604 | 0.73 | CDK5 (0.64) | CDK5CDK9GSK3AGSK3BDYRK1A | |
| SCHEMBL27591220 | 0.71 | SRD5A2 (0.52) | CDK5GSK3AGSK3BCCNA2CDK2 | |
| SCHEMBL5742541 | 0.71 | CDK4 (0.74) | CDK5CDK9GSK3AGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | US | disclosed |
| EP-1417188-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | Novo Nordisk A/S (DK) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003011843-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | GSK3B, GSK3A, GYS2 | CDK5 749/4885CDK9 1683/4885GSK3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.